Allianz Asset Management
DNLI icon

Allianz Asset Management’s Denali Therapeutics DNLI Stock Holding History

Allianz Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,400
Closed -$316K – 2149
2024
Q1 		$316K Hold
15,400
– – ﹤0.01% 1733
2023
Q4 		$330K Buy
15,400
+700
+5% +$13.9K ﹤0.01% 1955
2023
Q3 		$303K Hold
14,700
– – ﹤0.01% 2058
2023
Q2 		$434K Buy
14,700
+3,400
+30% +$95.6K ﹤0.01% 1772
2023
Q1 		$260K Hold
11,300
– – ﹤0.01% 2012
2022
Q4 		$314K Hold
11,300
– – ﹤0.01% 1807
2022
Q3 		$347K Sell
11,300
-3,520
-24% -$114K ﹤0.01% 1583
2022
Q2 		$436K Sell
14,820
-3,000
-17% -$78.6K ﹤0.01% 1925
2022
Q1 		$574K Sell
17,820
-18,325
-51% -$631K ﹤0.01% 2068
2021
Q4 		$1.61M Buy
36,145
+17,410
+93% +$825K ﹤0.01% 1699
2021
Q3 		$945K Sell
18,735
-4,720
-20% -$266K ﹤0.01% 1958
2021
Q2 		$1.84M Hold
23,455
– – ﹤0.01% 1496
2021
Q1 		$1.34M Sell
23,455
-8,805
-27% -$589K ﹤0.01% 1542
2020
Q4 		$2.7M Buy
+32,260
New +$1.95M ﹤0.01% 1230
2020
Q1 		– Sell
-33,154
Closed -$577K – 2534
2019
Q4 		$577K Sell
33,154
-28,062
-46% -$467K ﹤0.01% 2393
2019
Q3 		$952K Sell
61,216
-45
-0.1% -$860 ﹤0.01% 2150
2019
Q2 		$1.27M Sell
61,261
-38,561
-39% -$864K ﹤0.01% 2057
2019
Q1 		$2.32M Buy
99,822
+8,618
+9% +$180K ﹤0.01% 1800
2018
Q4 		$1.86M Sell
91,204
-132,076
-59% -$2.4M ﹤0.01% 1794
2018
Q3 		$4.85M Sell
223,280
-13,510
-6% -$223K ﹤0.01% 1568
2018
Q2 		$3.61M Buy
236,790
+500
+0.2% +$9.42K ﹤0.01% 1684
2018
Q1 		$4.65M Buy
236,290
+36,745
+18% +$755K ﹤0.01% 1562
2017
Q4 		$3.12M Buy
+199,545
New +$3.59M ﹤0.01% 1826

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Allianz Asset Management's DNLI Position: Q2 2024 in Review

Allianz Asset Management sold out of Denali Therapeutics (DNLI) in Q2 2024, closing a stake of 15,400 shares — an estimated $316K sold.

Allianz Asset Management first reported a position in DNLI in Q4 2017 and held it in 23 quarters. The position peaked at $4.85M in Q3 2018. 203 funds tracked by Wall St. Rank hold DNLI as of Q2 2024.

  • Allianz Asset Management reported no remaining Denali Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Allianz Asset Management sold 15,400 Denali Therapeutics shares in Q2 2024, an estimated $316K.
  • Allianz Asset Management first reported a position in Denali Therapeutics in Q4 2017 and held it in 23 quarters.
  • Allianz Asset Management's Denali Therapeutics position peaked at $4.85M in Q3 2018.
  • 203 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2024.

Based on Allianz Asset Management's 13F filing for Q2 2024, filed 13 Aug 2024.